ClinicalTrials.gg
Active, not recruitingNCT01475123Updated Sep 3, 2026

Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil

A Phase 4 interventional study of Nicorandil in Coronary Artery Disease and End Stage Renal Disease, sponsored by Kumamoto University. Active, not recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Kumamoto University · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
268
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Coronary Artery Disease with a site in Japan — 12 open to participants now, 21 under way, 2 of them phase 3. Coronary Artery Disease · Japan.

Enrollment
54th of 100
268 · median 445
Started
2008
with 3 others
Phase 4
36 of 134
1 open now
Primary completion
2011-06
later than 0 of 20 live
Registered
45th of 134
by date
Lead sponsor
7 of 134
Kumamoto University

Among the 134 studies in Coronary Artery Disease with a site in Japan, this one is the 54th largest by enrollment of the 100 interventional ones that give a count, is one of 4 that started in 2008, is one of 36 in phase 4, reaches primary completion later than 0 of the 20 other live ones, and was the 45th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

12 of the 134 studies in Coronary Artery Disease with a site in Japan are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Coronary Artery Disease with a site in Japan, or all of them as a file.
02

Study summary

Nicorandil is potentially effective to prevent cardiovascular events in patients with coronary artery disease (CAD) receiving hemodialysis. The purpose of this study is to prospectively investigate whether nicorandil is effective in reducing the incidence of cardiovascular events in patients with CAD on hemodialysis.

Read the detailed description

Patients on hemodialysis for end-stage renal disease are at high risk for death from ischemic heart disease. It was reported that nicorandil, a hybrid compound on adenosine triphosphate-sensitive potassium channel opener and nitric oxide door, was potentially effective to prevent cardiovascular events in patients with CAD receiving hemodialysis. Therefore, investigators prospectively examine whether nicorandil is effective in reducing the incidence of cardiovascular events in patients with CAD on hemodialysis.

The primary endpoint is a composite of cardiovascular death, sudden cardiac death, nonfatal myocardial infarction, hospitalization for recurrent symptomatic myocardial ischemia and stroke. The secondary endpoints are total mortality, revascularization therapy, hospitalization for heart failure, hospitalization for peripheral artery disease and newly onset of atrial fibrillation.

Patient population that needs to prove the hypothesis is estimate to be 400 cases in total (200 cases in each group). Investigators set the parameters which are need to calculate the number of study patients as follows; drop out rate 10%, an event rate of the primary end point for two years 50%, a risk reduction rate brought by nicorandil 60%, a statistical power 80% and two-sided significant level 0.05. Investigators referred the event rate and the risk reduction rate from the previous study by Ishi H et al. In this study, event rate of the primary end point for two years was 50% and the risk reduction brought by nicorandil was 60%. Event rate of the present study will be lower, because drug-eluting stents are widely used to prevent restenosis in the present era. Moreover, investigators include the patients underwent coronary bypass graft in the present study. In addition, non-cardiovascular mortality is high in the patients on hemodialysis. Considering all the various factors together, investigators estimated the study sample size.

03

Conditions studied

  • Coronary Artery Disease
  • End Stage Renal Disease

Keywords

  • Nicorandil
  • Randomized control study
  • Hemodialysis
  • Coronary Artery Disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligible patients are who meet the following criteria:

  • Patient with previously diagnosed coronary artery disease (significant coronary artery stenosis is defined as > 75% narrowing of the artery lumen)
  • Patients who continued hemodialysis for more than one month

Exclusion criteria

Exclusion Criteria:

  • Within one month after acute myocardial infarction
  • Within 3 months after coronary artery bypass graft (CABG)
  • Treatment with phosphodiesterase type 5 inhibitor
  • Candidates for carotid artery stenting
  • Severe disease requiring active medical treatment
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
268 participants (actual)

Study arms

  • Active comparator
    Nicorandil

    Nicorandil was administered orally (15mg/day).

    Drug: Nicorandil

  • No intervention
    Non-nicorandil

    Nicorandil was not administered.

Interventions

06

What researchers measure

Primary outcomes

  1. The primary endpoint is composite of :1) cardiovascular death 2)sudden cardiac death 3)nonfatal myocardial infarction 4)Hospitalization for recurrent symptomatic myocardial ischemia 5)stroke

    Time frame: 2 years

Secondary outcomes

  1. Total mortality

    Time frame: 2 years

  2. revascularization therapy

    Time frame: 2 years

  3. hospitalization for heart failure

    Time frame: 2 years

  4. hospitalization for peripheral artery disease

    Time frame: 2 years

  5. newly onset of atrial fibrillation

    Time frame: 2 years

07

Study locations

1 site
  • Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
    Kumamoto, 860-8556, Japan
08

References and documents

Publications

  • Ishii H, Toriyama T, Aoyama T, Takahashi H, Yamada S, Kasuga H, Ichimiya S, Kanashiro M, Mitsuhashi H, Maruyama S, Matsuo S, Naruse K, Matsubara T, Murohara T. Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther. 2007 Jan;29(1):110-22. doi: 10.1016/j.clinthera.2007.12.020. PubMed 17379051 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jun 2011 and a completion of Aug 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2011
First posted
Nov 21, 2011
Start
Jun 2008
Primary completionActual
Jun 2011
CompletionEst.
Aug 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01475123
Lead sponsor
Kumamoto University
Responsible party
Yasuhiro Nagayoshi (principal investigator, Kumamoto University) — Principal investigator
First posted
Nov 21, 2011
Start date
Jun 2008
Primary completion
Jun 2011
Completion
Aug 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Hisao Ogawa, MD, PhD
study chair · Kumamoto University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicorandil

Start the discussion